🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "major milestone" in the effort against drug-resistant strains of the pathogen, according to researchers.

An International Health Concern

Gonorrhoea infections are escalating globally, with data suggesting in excess of 82 million instances per year. Notably increased rates are observed in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely development in the face of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs at this time.”

Public health authorities are particularly alarmed about the surge in drug-resistant strains. The global health body has classified it as a "high-priority threat". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Gain Authorization

Zoliflodacin, also known as a brand name, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, was also approved in concurrent days. This drug, which is additionally indicated for UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin emerged from a unique collaborative effort for medication research. The non-profit organisation GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This approval represents a significant shift in the treatment of highly resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Testing Outcomes and Global Access

Based on findings released by a major medical journal, zoliflodacin cured the vast majority of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which combines two antibiotics. The trial enrolled over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the authority to license and sell the drug in a wide range of regions with limited resources.

Doctors directly involved have voiced hope. Access to a single-dose, oral treatment such as this is hailed as a "game-changer" for gonorrhoea control. This is viewed as crucial to lessen the impact of the disease for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.